Integration of a severe immune-related adverse events predictive model with efficacy biomarkers enables precise stratification in NSCLC immunotherapy: insights from the phase 3 ORIENT-11 study
Severe immune-related adverse events (irAEs) compromise the outcomes of immune checkpoint inhibitors (ICIs). However, in routine practice, clinicians still lack biomarkers that can prospectively disentangle antitumor efficacy from the risk of severe irAEs, resulting in largely empirical, one-size-fits-all use of...